| [1] |
de Lope CR, Tremosini S, Forner A, et al. Management of HCC[J]. J Hepatol, 2012, 56 Suppl 1:S75-87.
|
| [2] |
Mazzaferro V, Lencioni R, Majno P. Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation[J]. Semin Liver Dis, 2014, 34(4):415-426.
|
| [3] |
Itamoto T, Nakahara H, Amano H, et al. Repeat hepatectomy for recurrent hepatocellular carcinoma[J]. Surgery, 2007, 141(5):589-597.
|
| [4] |
Kobayashi T, Aikata H, Hatooka M, et al. Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma[J]. Eur Radiol, 2015, 25(11):3272-3281.
|
| [5] |
Nuta J, Shingaki N, Ida Y, et al. Irregular defects in hepatocellular carcinomas during the Kupffer phase of contrast-enhanced ultrasonography with perfluorobutane microbubbles: pathological features and metastatic recurrence after surgical resection[J]. Ultrasound Med Biol, 2017, 43(9):1829-1836.
|
| [6] |
Ishii T, Numata K, Hao Y, et al. Evaluation of hepatocellular carcinoma tumor vascularity using contrast-enhanced ultrasonography as a predictor for local recurrence following radiofrequency ablation[J]. Eur J Radiol, 2017, 89:234-241.
|
| [7] |
Zhao H, Yao JL, Wang Y, et al. Detection of small hepatocellular carcinoma: comparison of dynamic enhancement magnetic resonance imaging and multiphase multirow-detector helical CT scanning[J]. World J Gastroenterol, 2007, 13(8):1252-1256．
|
| [8] |
Zhou Y, He L, Huang Y, et al. CT-based radiomics signature: a potential biomarker for preoperative prediction of early recurrence in hepatocellular carcinoma[J]. Abdom Radiol, 2017, 42(6):1695-1704.
|
| [9] |
Zhang W, Lai SL, Chen J, et al. Validated preoperative computed tomography risk estimation for postoperative hepatocellular carcinoma recurrence[J]. World J Gastroenterol, 2017, 23(35):6467-6473.
|
| [10] |
Inoue M, Ogasawara S, Chiba T, et al. Presence of non-hypervascular hypointense nodules on Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2017, 32(4):908-915.
|
| [11] |
Ahn SJ, Kim JH, Park SJ, et al. Hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MR imaging can predict early recurrence after curative resection using image features and texture analysis[J]. Abdom Radiol, 2019, 44(2):539-548.
|
| [12] |
Kitao A, Zen Y, Matsui O, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging-correlation with molecular transporters and histopathologic features[J]. Radiology, 2010, 256(3):817-826.
|
| [13] |
Sun L, Guan YS, Pan WM, et al. Metabolic restaging of hepatocellular carcinoma using whole-body 18F-FDG PET/CT[J]. World J Hepatol, 2009, 1(1):90-97.
|
| [14] |
Kim YK, Lee KW, Cho SY, et al. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients[J]. Liver Transpl, 2010, 16(6):767-772.
|
| [15] |
Liao X, Wei J, Li Y, et al.18F-FDG PET with or without CT in the diagnosis of extrahepatic metastases or local residual/recurrent hepatocellular carcinoma[J]. Medicine, 2018, 97(34):e11970.
|
| [16] |
Siripongsakun S, Wei SH, Lin S, et al. Evaluation of alpha-fetoprotein in detecting hepatocellular carcinoma recurrence after radiofrequency ablation[J]. J Gastroenterol Hepatol, 2014, 29(1): 157-164.
|
| [17] |
Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol, 2011, 29(36):4781-4788.
|
| [18] |
Cho HJ, Kim SS, Nam JS, et al. Low levels of circulating microRNA-26a/29a as poor prognostic markers in patients with hepatocellular carcinoma who underwent curative treatment[J]. Clin Res Hepatol Gastroenterol, 2017, 41(2):181-189.
|
| [19] |
Iwahashi S, Shimada M, Utsunomiya T, et al. Epithelial-mesenchymal transition-related genes are linked to aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation[J]. Cancer Lett, 2016, 375(1):47-50.
|
| [20] |
Shelat VG, Serin K, Samim M, et al. Outcomes of repeat laparoscopic liver resection compared to the primary resection[J]. World J Surg, 2014, 38(12):3175-3180.
|
| [21] |
Ome Y, Hashida K, Yokota M, et al. The feasibility and efficacy of pure laparoscopic repeat hepatectomy[J]. Surg Endosc, 2018, 32(8): 3474-3479.
|
| [22] |
Forner A, Reig ME, de Lope CR, et al. Current strategy for staging and treatment: the BCLC update and future prospects[J]. Semin Liver Dis, 2010, 30(1):61-74.
|
| [23] |
Muaddi H, Al-Adra DP, Beecroft R, et al. Liver transplantation is equally effective as a salvage therapy for patients with hepatocellular carcinoma recurrence following radiofrequency ablation or liver resection with curative intent[J]. Ann Surg Oncol, 2018, 25(4):991-999.
|
| [24] |
Zhang X, Li C, Wen T, et al. Treatment for intrahepatic recurrence after curative resection of hepatocellular carcinoma: salvage liver transplantation or re-resection/radiofrequency ablation?a retrospective cohort study[J]. Int J Surg, 2017, 46:178-185.
|
| [25] |
Lim C, Shinkawa H, Hasegawa K, et al. Salvage liver transplantation or repeat hepatectomy for recurrent hepatocellular carcinoma:an intent-to-treat analysis[J]. Liver Transpl, 2017, 23(12):1553-1563.
|
| [26] |
Song KD, Lee MW, Rhim H, et al. Percutaneous US/MRI fusion-guided radiofrequency ablation for recurrent subcentimeter hepatocellular carcinoma: technical feasibility and therapeutic outcomes[J]. Radiology, 2018, 288(3):878-886.
|
| [27] |
Song KD, Lim HK, Rhim H, et al. Repeated hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma after hepatic resection: a propensity score matching study[J]. Radiology, 2015, 275(2):599-608.
|
| [28] |
Peng Z, Chen S, Wei M, et al. Advanced recurrent hepatocellular carcinoma: treatment with sorafenib alone or in combination with transarterial chemoembolization and radiofrequency ablation[J]. Radiology, 2018, 287(2):705-714.
|
| [29] |
Wang DY, Liu L, Qi XS, et al. Hepatic re-resection versus transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma after initial resection: a systematic review and meta-analysis[J]. Asian Pac J Cancer Prev, 2015, 16(13):5573-5578.
|
| [30] |
Choi GH, Kim DH, Kang CM, et al. Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma?[J]. World J Surg, 2007, 31(12):2370-2377.
|
| [31] |
Tao Q, He W, Li B, et al. Resection versus resection with preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma recurrence[J]. J Cancer, 2018, 9(16):2778-2785.
|
| [32] |
Leung DK, Divgi C. Trans-arterial I-131 lipiodol therapy of liver tumors//Aktolun C, Goldsmith SJ. Nuclear Medicine Therapy[M]. Berlin: Springer, 2013:199-205.
|
| [33] |
Lin M, Huang J, Zhang D, et al. Hepatoma-targeted radionuclide immune albumin nanospheres: (131) I-antiAFPMcAb-GCV-BSA-NPs[J]. Anal Cell Pathol, 2016:9142198.
|
| [34] |
Sato K, Lewandowski RJ, Bui JT, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere(R)): assessment of hepatic arterial embolization[J]. Cardiovasc Intervent Radiol, 2006, 29(4):522-529.
|
| [35] |
Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres:a comprehensive report of long-term outcomes[J]. Gastroenterology, 2010, 138(1): 52-56.
|
| [36] |
Wang SN, Chuang SC, Lee KT. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: a pilot study[J]. Hepatol Res, 2014, 44(5):523-531.
|
| [37] |
Kang SH, Cho H, Cho EJ. et al. Efficacy of sorafenib for the treatment of post-transplant hepatocellular carcinoma recurrence[J].J Korean Med Sci, 2018, 33(45):e283.
|
| [38] |
Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis[J]. Hepatology, 2006, 44(6):1543-1554.
|
| [39] |
Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer[J]. N Engl J Med, 2009, 361(15):1437-1447.
|
| [40] |
Nakamoto Y, Mizukoshi E, Kitahara M, et al．Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization[J]. Clin Exp Immunol, 2011, 163(2):165-177．
|
| [41] |
Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J]. Gastroenterology, 2015, 148(7):1383-1391, e6.
|
| [42] |
Ranganath HA, Panella TJ. Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma[J].J Immunother, 2015, 38(5): 211.
|
| [43] |
汪国营，唐晖，张英才，等．程序性死亡受体（PD）-1单克隆抗体治疗肝癌肝移植术后复发诱发急性免疫性肝炎：附1例报告[J].器官移植，2016(1):44-47.
|